Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Retinal Biologics Market

ID: MRFR/Pharma/17398-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026

US Retinal Biologics Market Research Report: Size, Share, Trend Analysis By Drug Class (TNF-a Inhibitor, VEGF-A Antagonist), By Indication (Macular Degeneration, Diabetic Retinopathy, Uveitis, Others) and By Distribution Channel (Hospitals and Clinics, Pharmacies, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Retinal Biologics Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Life Sciences, BY Drug Class (USD Million)
  49.     4.1.1 TNF-a inhibitor
  50.     4.1.2 VEGF-A antagonist
  51.   4.2 Life Sciences, BY Indication (USD Million)
  52.     4.2.1 macular degeneration
  53.     4.2.2 diabetic retinopathy
  54.     4.2.3 uveitis
  55.     4.2.4 others
  56.   4.3 Life Sciences, BY Distribution Channel (USD Million)
  57.     4.3.1 hospitals and clinics
  58.     4.3.2 pharmacies
  59.     4.3.3 others
  60. 5 SECTION V: COMPETITIVE ANALYSIS
  61.   5.1 Competitive Landscape
  62.     5.1.1 Overview
  63.     5.1.2 Competitive Analysis
  64.     5.1.3 Market share Analysis
  65.     5.1.4 Major Growth Strategy in the Life Sciences
  66.     5.1.5 Competitive Benchmarking
  67.     5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  68.     5.1.7 Key developments and growth strategies
  69.       5.1.7.1 New Product Launch/Service Deployment
  70.       5.1.7.2 Merger & Acquisitions
  71.       5.1.7.3 Joint Ventures
  72.     5.1.8 Major Players Financial Matrix
  73.       5.1.8.1 Sales and Operating Income
  74.       5.1.8.2 Major Players R&D Expenditure. 2023
  75.   5.2 Company Profiles
  76.     5.2.1 Regeneron Pharmaceuticals (US)
  77.       5.2.1.1 Financial Overview
  78.       5.2.1.2 Products Offered
  79.       5.2.1.3 Key Developments
  80.       5.2.1.4 SWOT Analysis
  81.       5.2.1.5 Key Strategies
  82.     5.2.2 Novartis (CH)
  83.       5.2.2.1 Financial Overview
  84.       5.2.2.2 Products Offered
  85.       5.2.2.3 Key Developments
  86.       5.2.2.4 SWOT Analysis
  87.       5.2.2.5 Key Strategies
  88.     5.2.3 Roche (CH)
  89.       5.2.3.1 Financial Overview
  90.       5.2.3.2 Products Offered
  91.       5.2.3.3 Key Developments
  92.       5.2.3.4 SWOT Analysis
  93.       5.2.3.5 Key Strategies
  94.     5.2.4 Bayer (DE)
  95.       5.2.4.1 Financial Overview
  96.       5.2.4.2 Products Offered
  97.       5.2.4.3 Key Developments
  98.       5.2.4.4 SWOT Analysis
  99.       5.2.4.5 Key Strategies
  100.     5.2.5 Amgen (US)
  101.       5.2.5.1 Financial Overview
  102.       5.2.5.2 Products Offered
  103.       5.2.5.3 Key Developments
  104.       5.2.5.4 SWOT Analysis
  105.       5.2.5.5 Key Strategies
  106.     5.2.6 Santen Pharmaceutical (JP)
  107.       5.2.6.1 Financial Overview
  108.       5.2.6.2 Products Offered
  109.       5.2.6.3 Key Developments
  110.       5.2.6.4 SWOT Analysis
  111.       5.2.6.5 Key Strategies
  112.     5.2.7 Alcon (CH)
  113.       5.2.7.1 Financial Overview
  114.       5.2.7.2 Products Offered
  115.       5.2.7.3 Key Developments
  116.       5.2.7.4 SWOT Analysis
  117.       5.2.7.5 Key Strategies
  118.     5.2.8 Horizon Therapeutics (IE)
  119.       5.2.8.1 Financial Overview
  120.       5.2.8.2 Products Offered
  121.       5.2.8.3 Key Developments
  122.       5.2.8.4 SWOT Analysis
  123.       5.2.8.5 Key Strategies
  124.     5.2.9 Apellis Pharmaceuticals (US)
  125.       5.2.9.1 Financial Overview
  126.       5.2.9.2 Products Offered
  127.       5.2.9.3 Key Developments
  128.       5.2.9.4 SWOT Analysis
  129.       5.2.9.5 Key Strategies
  130.   5.3 Appendix
  131.     5.3.1 References
  132.     5.3.2 Related Reports
  133. 6 LIST OF FIGURES
  134.   6.1 MARKET SYNOPSIS
  135.   6.2 US MARKET ANALYSIS BY DRUG CLASS
  136.   6.3 US MARKET ANALYSIS BY INDICATION
  137.   6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  138.   6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
  139.   6.6 RESEARCH PROCESS OF MRFR
  140.   6.7 DRO ANALYSIS OF LIFE SCIENCES
  141.   6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
  142.   6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
  143.   6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
  144.   6.11 LIFE SCIENCES, BY DRUG CLASS, 2024 (% SHARE)
  145.   6.12 LIFE SCIENCES, BY DRUG CLASS, 2024 TO 2035 (USD Million)
  146.   6.13 LIFE SCIENCES, BY INDICATION, 2024 (% SHARE)
  147.   6.14 LIFE SCIENCES, BY INDICATION, 2024 TO 2035 (USD Million)
  148.   6.15 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  149.   6.16 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  150.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  151. 7 LIST OF TABLES
  152.   7.1 LIST OF ASSUMPTIONS
  153.     7.1.1
  154.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  155.     7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  156.     7.2.2 BY INDICATION, 2025-2035 (USD Million)
  157.     7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  158.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  159.     7.3.1
  160.   7.4 ACQUISITION/PARTNERSHIP
  161.     7.4.1

US Life Sciences Market Segmentation

Life Sciences By Drug Class (USD Million, 2025-2035)

  • TNF-a inhibitor
  • VEGF-A antagonist

Life Sciences By Indication (USD Million, 2025-2035)

  • macular degeneration
  • diabetic retinopathy
  • uveitis
  • others

Life Sciences By Distribution Channel (USD Million, 2025-2035)

  • hospitals and clinics
  • pharmacies
  • others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions